Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGI-004
- Development stage
- Unknown
- Lead developer
- Aravis
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
AGI-004 is a once-daily, controlled-release transdermal patch formulation of mecamylamine, a non-selective nicotinic acetylcholine receptor antagonist and ganglion blocker. Developed by AGI Therapeutics, the drug was designed as a novel anti-diarrheal agent for the treatment of chemotherapy-induced diarrhea (CID) and diarrhea-predominant irritable bowel syndrome (d-IBS). By utilizing a transdermal delivery system, AGI-004 aims to provide sustained drug exposure while minimizing the peak-to-trough fluctuations associated with oral administration, thereby reducing traditional non-gastrointestinal side effects such as hypotension while maintaining therapeutic effects on gut motility. Phase II clinical trials demonstrated positive results in patients with functional diarrhea and CID, showing good tolerability and a reduction in diarrheal symptoms.
- Other names
- mecamylamine transdermal patch
02
Targets
α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on AGI-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGI-004.